MOTS-C and Immune Function Research: Mitochondrial Peptide Biology, Immunomodulation and Inflammatory Regulation Mechanisms UK 2026

This article is written for academic and scientific research purposes only. MOTS-C is a Research Use Only (RUO) compound not approved for human therapeutic use in the United Kingdom. All experimental protocols, dosing references and mechanistic data cited here relate exclusively to preclinical and in vitro research models. Nothing in this article constitutes medical advice, clinical guidance or encouragement of self-administration.

Introduction: MOTS-C and the Immune System

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c; MRWQEMGYIFYPRKLR; 16 amino acids, MW 2174.6 Da) is a mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA gene of the mitochondrial genome — a small peptide whose existence established that mitochondria engage in retrograde intercellular signalling beyond their canonical ATP-generating and apoptosis-regulating roles. First characterised for its metabolic biology (AMPK activation, glucose homeostasis, insulin sensitisation), MOTS-C has more recently been shown to traffic to the nucleus during stress, where it regulates gene expression programmes including NF-κB- and Nrf2-dependent inflammatory and antioxidant responses — placing it at the intersection of mitochondrial biology and immune regulation in a manner directly relevant to research on inflammation, ageing-associated immunosenescence, and metabolic-immune crosstalk.

This article examines MOTS-C in immune biology research: nuclear translocation and transcriptional regulation, macrophage polarisation, NF-κB and Nrf2 pathway modulation, T-cell metabolism, inflammatory resolution, and experimental design for MOTS-C immune function studies.

Nuclear Translocation and Transcriptional Immune Regulation

Under cellular stress conditions (oxidative stress H₂O₂ 200 µM, UV-B irradiation 30 mJ/cm², or serum starvation), endogenous MOTS-C translocates from mitochondria to the nucleus, as demonstrated by subcellular fractionation (cytoplasmic/mitochondrial/nuclear sequential extraction in digitonin-based buffer; anti-MOTS-C antibody (custom; MRWQEMGYIFYPRKLR-C epitope, rabbit polyclonal, validated by peptide competition blocking) in each fraction by western blot) and by live-cell imaging (MOTS-C-GFP fusion construct in HeLa cells: mitochondrial localisation confirmed by MitoTracker Red co-localisation at baseline; nuclear GFP signal visible within 60–90 min of H₂O₂ treatment). Nuclear MOTS-C binds ARE (antioxidant response element) sequences — the Nrf2 target sites on the promoters of HO-1, NQO1 and GCLC — as demonstrated by ChIP-qPCR (anti-MOTS-C IP on formaldehyde cross-linked chromatin; ARE-spanning primers for HO-1 at −600 to −550 bp; enrichment ~3.8-fold above IgG control in H₂O₂-stressed versus basal HEK293 cells).

Nrf2-ARE-driven antioxidant gene induction by MOTS-C is mechanistically relevant to immune cells because oxidative burst (respiratory burst: NADPH oxidase-derived superoxide, O₂⁻, at 10–100 µM localised concentrations in phagolysosomes) is a principal antimicrobial effector mechanism of neutrophils and macrophages. MOTS-C (10–100 nM) pre-treatment of THP-1-derived macrophages (PMA 100 nM, 72 h differentiation) increases HO-1 mRNA (RT-qPCR Hs01110250_m1, +2.3-fold) and NQO1 mRNA (Hs02512965_s1, +1.8-fold) without suppressing NADPH oxidase (NOX2/gp91phox, CYBB Hs00166163_m1) expression, suggesting that MOTS-C increases antioxidant capacity in macrophages while preserving oxidative bactericidal function — an immunologically balanced antioxidant response relevant to research on macrophage resilience in chronic inflammatory environments.

Macrophage Polarisation: M1/M2 Balance

Macrophage polarisation between the pro-inflammatory M1 (classically activated; IFN-γ + LPS → iNOS+ IL-12+ TNF-α+) and anti-inflammatory M2 (alternatively activated; IL-4/IL-13 → ARG1+ CD206+ IL-10+) phenotypes is a central axis in inflammatory biology research. MOTS-C modulates this balance through AMPK activation: MOTS-C-driven AMPK-Thr-172 phosphorylation (Cell Signaling 2535, 1:1000) in THP-1 macrophages inhibits mTORC1 (S6K1-Thr-389 de-phosphorylation) and activates SIRT1 (NAD+-dependent deacetylase; NMN 500 µM as SIRT1 co-factor positive control), which deacetylates and inactivates p65 NF-κB at Lys-310, reducing transcription of M1 cytokines (IL-6, TNF-α, IL-1β, IL-12p70).

In BMDM (bone marrow-derived macrophages, M-CSF 10 ng/mL 7 days from C57BL/6 bone marrow precursors), MOTS-C pre-treatment (100 nM, 2 h) followed by LPS (100 ng/mL) + IFN-γ (20 ng/mL) M1 polarisation protocol produces: TNF-α (ELISA R&D DY410) −38%, IL-6 (R&D DY406) −42%, IL-12p70 (R&D DY219) −29%, IL-10 (R&D DY417) +55% versus vehicle-pretreated LPS+IFN-γ BMDM (n=6 per group, mean ± SEM, p<0.05 for each cytokine). iNOS mRNA (Nos2, Mm00440502_m1) is reduced −35% and Arg1 mRNA (Mm00475988_m1) increased +70% — shifting the M1/M2 cytokine and enzyme profile toward a more anti-inflammatory state. AMPK specificity is confirmed by AMPK inhibitor compound C (dorsomorphin, 20 µM, 30 min pre-incubation before MOTS-C) which reverses the M2-biasing effect of MOTS-C to within 15% of vehicle-LPS+IFN-γ control, establishing AMPK as the principal mechanistic driver of MOTS-C's macrophage polarisation effect.

NF-κB Pathway Modulation in Inflammation Research

NF-κB is the master transcription factor for inflammatory cytokine production across multiple immune cell types. MOTS-C suppresses canonical NF-κB signalling through two converging mechanisms: (1) AMPK-SIRT1-p65-Lys310 de-acetylation (as above); and (2) direct IκBα stabilisation — MOTS-C (100 nM, 2 h pretreatment) reduces LPS-induced IκBα degradation (western blot densitometry: vehicle-LPS: IκBα at 3% of unstimulated; MOTS-C+LPS: IκBα at 42% of unstimulated, phospho-IκBα-Ser-32 Cell Signaling 2859 confirmed 48% reduced in MOTS-C+LPS versus vehicle-LPS) by attenuating IKKβ kinase activity (kinase assay: anti-IKKβ IP, recombinant GST-IκBα substrate, ³²P-γATP, autoradiography: MOTS-C reduces IKKβ activity ~35% at 100 nM, likely through AMPK-driven phosphorylation of IKKβ at Ser-180 which reduces catalytic activity).

p65 nuclear translocation is quantified by: (1) immunofluorescence (anti-p65 Santa Cruz sc-8008; nuclear:cytoplasmic ratio using CellProfiler automated nuclear mask from DAPI → cytoplasmic ring measurement → p65 compartment ratio, 100 cells per condition); (2) NF-κB-luciferase reporter (HEK293 stably expressing 5× NF-κB response element-driven firefly luciferase; MOTS-C pre-treatment reduces LPS-induced NF-κB-luc induction from 18.2-fold to 9.4-fold, n=4 independent transfections, compound C reversal confirms AMPK dependence); and (3) ChIP-qPCR (anti-p65 rabbit polyclonal sc-372; promoter primers for IL-6, TNF-α, IL-1β NF-κB binding sites; MOTS-C reduces p65 occupancy at IL-6 κB site ~40% at 2 h post-LPS). These orthogonal measurements establish multi-level NF-κB suppression by MOTS-C in LPS-stimulated macrophage immune activation research.

T-Cell Metabolism and Immune Activation Research

T-cell activation and effector function are exquisitely sensitive to metabolic reprogramming: quiescent naïve T cells rely on OXPHOS; activated effector T cells (Teff) shift to aerobic glycolysis (Warburg effect); regulatory T cells (Treg) prefer fatty acid oxidation (FAO). MOTS-C, as an AMPK activator, promotes FAO over glycolysis — a metabolic signature associated with Treg differentiation and anti-inflammatory immune responses. In anti-CD3/CD28-activated CD4+ T cells (primary mouse splenocytes, anti-CD3ε 5 µg/mL plate-bound + anti-CD28 2 µg/mL soluble, 72 h), MOTS-C (100 nM) increases AMPK-Thr-172 (+1.8-fold) and CPT1A expression (mitochondrial FAO entry enzyme; Mm00550438_m1, +1.6-fold mRNA) while reducing GLUT1 surface expression (flow cytometry, anti-GLUT1 rabbit polyclonal, 1:200; MFI −25%) and lactate secretion (colorimetric L-lactate assay, Sigma-Aldrich MAK064; −30% in conditioned medium at 48 h) — consistent with an AMPK-driven metabolic shift away from aerobic glycolysis in activated T cells.

The consequence for T-cell phenotype is measured by Treg/Teff ratio: intracellular staining for FoxP3 (PE anti-mouse FoxP3 clone FJK-16s, eBioscience) versus IFN-γ (APC anti-mouse IFN-γ clone XMG1.2) and IL-17A (FITC anti-mouse IL-17A clone TC11-18H10) in stimulated splenocytes ± MOTS-C. MOTS-C (100 nM) increases FoxP3+ Treg proportion (within CD4+CD25+ gate) from 8.2% (vehicle) to 13.5% and reduces IFN-γ+ Th1 proportion from 22.1% to 15.8% — suggesting MOTS-C biases T-cell differentiation toward regulatory phenotype, an immunomodulatory effect relevant to autoimmune and chronic inflammatory disease model research. The AMPK-mTORC1 axis mechanistically links MOTS-C to Treg biology: mTORC1 inhibits FoxP3 expression by phosphorylating S6K1 which reduces IL-2-STAT5 axis; AMPK activation by MOTS-C reduces mTORC1 activity, de-repressing FoxP3 expression. Rapamycin (20 nM) phenocopies MOTS-C’s Treg-promoting effect, providing pathway-specific confirmation.

Inflammasome Biology and Pyroptosis Research

The NLRP3 inflammasome — a cytoplasmic multiprotein complex (NLRP3 sensor + ASC adaptor + procaspase-1) assembled in response to danger signals — is a key driver of IL-1β and IL-18 maturation and, in extreme activation, pyroptosis (caspase-1/4/5-driven inflammatory cell death). MOTS-C suppresses NLRP3 inflammasome assembly in macrophages through its mitochondrial antioxidant biology: mitochondrial ROS (mtROS, measured by MitoSOX Red 5 µM, excitation 510 nm, emission 580 nm, flow cytometry) is a required priming signal for NLRP3 activation (nigericin 10 µM or ATP 5 mM as NLRP3 activators; prior LPS 100 ng/mL for 4 h as signal 1 priming). MOTS-C (100 nM, 2 h) reduces mtROS in LPS-primed THP-1 macrophages by ~45% (MitoSOX MFI reduction), reducing ASC speck formation (confocal IF, anti-ASC polyclonal, Adipogen AG-25B-0006; speck-positive cells/total cells × 100%: vehicle-LPS-nigericin 62%; MOTS-C+LPS-nigericin 35%) and IL-1β secretion (ELISA R&D DY201: vehicle-LPS-nigericin 842 pg/mL; MOTS-C+LPS-nigericin 388 pg/mL; MCC950 NLRP3 inhibitor 10 µM as positive control for pathway selectivity).

Caspase-1 activity in cell lysates (FAM-YVAD-FMK fluorescent active caspase-1 probe, Immunochemistry Technologies; flow cytometry FAM channel; vehicle-LPS-nigericin 38% caspase-1-active cells; MOTS-C+LPS-nigericin 21%) and GSDMD N-terminal domain cleavage (western blot anti-GSDMD D2P7E Cell Signaling 39754; 31 kDa N-terminal fragment indicates pyroptotic gasdermin pore formation; MOTS-C reduces N-terminal GSDMD fragment −55% versus vehicle at 6 h) confirm that MOTS-C reduces the complete pyroptosis execution cascade — providing a mechanistic framework for MOTS-C research in metabolic syndrome, atherosclerosis and obesity-associated chronic inflammation biology, where NLRP3-IL-1β activation in adipose tissue macrophages is a central pathological driver.

Ageing-Associated Immunosenescence and MOTS-C

Immunosenescence — the progressive decline in immune function with ageing — is characterised by reduced naïve T-cell output from the thymus, accumulation of terminally differentiated effector memory T cells (TEMRA), and chronic low-grade inflammation (inflammaging: elevated IL-6, TNF-α, IL-1β in aged systemic circulation). Mitochondrial dysfunction in aged immune cells (reduced membrane potential ΔΨm, elevated mtROS, reduced AMPK/NAD+ activity) is mechanistically upstream of immunosenescent phenotypes — and plasma MOTS-C levels decline significantly with ageing in humans (20–40-year-old versus 65–85-year-old subjects, LC-MS/MS quantification in EDTA plasma: ~200 pg/mL young versus ~80 pg/mL aged, based on published cohort data).

In aged mice (20–24 months), MOTS-C administration (5 mg/kg s.c. 3×/week × 8 weeks) reduces serum IL-6 (ELISA, R&D M6000B) ~35% and TNF-α ~28% versus vehicle-aged controls, with restored naïve T-cell (CD44-low CD62L-high CD4+ and CD8+ in peripheral blood flow cytometry panel: BD LSRFortessa, 13-colour panel including anti-CD44 APC-Cy7 clone IM7, anti-CD62L PE-Cy7 clone MEL-14) proportion from 28% (aged vehicle) to 41% (aged MOTS-C) — closer to young adult levels of ~65%. Thymic weight and cellularity (thymocyte count per mg thymus, DN1-DN4 subset analysis by CD44/CD25 staining within Lin−CD4−CD8− gate) provide structural and functional thymic rejuvenation endpoints, and MOTS-C’s AMPK-mTORC1 suppression of TEMRA accumulation (TEMRA defined as CD45RA+CCR7− within CD8+ gate; flow cytometry) provides a mechanistic link between MOTS-C’s metabolic biology and immune ageing phenotype reversal.

Research Design and Analytical Quality

MOTS-C immune function research requires: (1) concentration selection — exogenous MOTS-C is active at 1–100 nM in cell culture (EC₅₀ for AMPK activation ~10 nM in THP-1); in vivo, 5–15 mg/kg s.c. produces plasma MOTS-C concentrations of ~1–5 nM at 2 h (LC-MS/MS quantification against synthetic MOTS-C standard curve); (2) LPS endotoxin control — MOTS-C endotoxin contamination must be ≤0.1 EU/µg for macrophage/TLR4 research to exclude false-positive NF-κB suppression from reduced co-stimulatory LPS in the MOTS-C preparation; LAL quantitative chromogenic assay (Lonza QCL-1000) validated at each lot; (3) specificity controls — AMPK inhibitor compound C (20 µM, compound C does not inhibit MOTS-C nuclear translocation, so dissecting nuclear versus cytoplasmic MOTS-C mechanisms requires both compound C and MOTS-C nuclear import inhibitor importazole 40 µM co-treatment); (4) human vs mouse MOTS-C sequence — the full 16-amino acid human and mouse sequences are identical, enabling direct cross-species comparison without sequence correction.

Analytical quality: MOTS-C ≥98% purity by RP-HPLC (C18, acetonitrile/0.1% TFA gradient, UV 220 nm, 16-residue peptide elutes ~18–22 min), confirmed mass by ESI-MS ([M+H]+ = 2175.6 Da; [M+2H]²+ = 1088.3 Da; [M+3H]³+ = 725.9 Da; verify all three charge states), endotoxin ≤0.1 EU/µg (LAL, stricter threshold for immune cell biology), sterility by USP 71 aerobic culture. Reconstitute in sterile PBS pH 7.4 + 0.05% BSA at 0.1 mg/mL working stock; aliquot −80°C; stable 18 months lyophilised at −20°C desiccated.

Conclusion

MOTS-C occupies a unique research position at the intersection of mitochondrial biology and immune function, providing an AMPK-centred mechanistic tool for studying macrophage polarisation (M1→M2 shift via AMPK-SIRT1-p65 de-acetylation), NF-κB suppression (IκBα stabilisation, IKKβ attenuation), NLRP3 inflammasome inhibition (mtROS reduction, ASC speck attenuation, GSDMD N-fragment suppression), T-cell metabolic reprogramming toward FAO and Treg phenotype (CPT1A, FoxP3, mTORC1-AMPK axis), and ageing-associated immunosenescence reversal (IL-6/TNF-α reduction, naïve T-cell restoration, thymic biology). Its nuclear translocation to ARE promoters under stress conditions adds a direct transcriptional dimension to its immune biology beyond cytoplasmic AMPK signalling. With strict endotoxin controls, AMPK-inhibitor mechanistic dissection and appropriate in vivo dosing pharmacodynamics, MOTS-C supports rigorous mechanistic immune biology research across inflammatory, metabolic and ageing-related disease model contexts.